Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Lymphoma, Non-Hodgkin"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 41-60 z 3129
Tytuł:
Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL.
Autorzy:
Susilo ME; Genentech Inc., South San Francisco, California, USA.
Li CC; Genentech Inc., South San Francisco, California, USA.
Gadkar K; Genentech Inc., South San Francisco, California, USA.
Hernandez G; Genentech Inc., South San Francisco, California, USA.
Huw LY; Genentech Inc., South San Francisco, California, USA.
Jin JY; Genentech Inc., South San Francisco, California, USA.
Yin S; Genentech Inc., South San Francisco, California, USA.
Wei MC; Genentech Inc., South San Francisco, California, USA.
Ramanujan S; Genentech Inc., South San Francisco, California, USA.
Hosseini I; Genentech Inc., South San Francisco, California, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 Jul; Vol. 16 (7), pp. 1134-1148. Date of Electronic Publication: 2023 Mar 23.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Lymphoma, Non-Hodgkin*/drug therapy
Humans ; T-Lymphocytes ; B-Lymphocytes ; Biomarkers
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Primary breast lymphoma: a case series and review of the literature.
Autorzy:
Sakhri S; Surgical Oncology Department, Salah Azaiez Institute of Oncology, Tunis, Tunisia.
Aloui M; Surgical Oncology Department, Salah Azaiez Institute of Oncology, Tunis, Tunisia. .
Bouhani M; Surgical Oncology Department, Salah Azaiez Institute of Oncology, Tunis, Tunisia.
Bouaziz H; Surgical Oncology Department, Salah Azaiez Institute of Oncology, Tunis, Tunisia.
Kamoun S; Pathology Department, Salah Azaiez Institute of Oncology, Tunis, Tunisia.
Slimene M; Surgical Oncology Department, Salah Azaiez Institute of Oncology, Tunis, Tunisia.
Ben Dhieb T; Surgical Oncology Department, Salah Azaiez Institute of Oncology, Tunis, Tunisia.
Pokaż więcej
Źródło:
Journal of medical case reports [J Med Case Rep] 2023 Jun 28; Vol. 17 (1), pp. 290. Date of Electronic Publication: 2023 Jun 28.
Typ publikacji:
Review; Journal Article; Case Reports
MeSH Terms:
Lymphoma, Follicular*
Lymphoma, Non-Hodgkin*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/diagnostic imaging
Lymphoma, Large B-Cell, Diffuse*/therapy
Lymphoma, Large B-Cell, Diffuse*/pathology
Lymphoma, T-Cell*
Humans ; Middle Aged ; Adolescent ; Young Adult ; Adult ; Aged ; Aged, 80 and over ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The epidemiology of haematological cancers in Sarawak, Malaysia (1996 to 2015).
Autorzy:
Kuan JW; Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak (UNIMAS), 94300, Kota Samarahan, Sarawak, Malaysia. .
Su AT; Department of Community Medicine and Public Health, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak (UNIMAS), Kota Samarahan, Sarawak, Malaysia.
Wahab M; Sarawak State Health Department, Ministry of Health, Kuching, Sarawak, Malaysia.
Hamdan A; Sarawak State Health Department, Ministry of Health, Kuching, Sarawak, Malaysia.
Hashim J; Department of Community Medicine and Public Health, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak (UNIMAS), Kota Samarahan, Sarawak, Malaysia.
Kiyu A; Department of Community Medicine and Public Health, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak (UNIMAS), Kota Samarahan, Sarawak, Malaysia.
Ooi CH; Sarawak State Health Department, Ministry of Health, Kuching, Sarawak, Malaysia.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Jun 19; Vol. 23 (1), pp. 563. Date of Electronic Publication: 2023 Jun 19.
Typ publikacji:
Journal Article
MeSH Terms:
Hematologic Neoplasms*/epidemiology
Multiple Myeloma*
Lymphoma, Non-Hodgkin*/epidemiology
Leukemia, Myeloid, Acute*
Adult ; Humans ; Male ; Child ; Adolescent ; Female ; Malaysia/epidemiology ; Incidence ; Registries
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition.
Autorzy:
Coats JT; Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
Tauro S; Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
Sutherland C; Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. .
Pokaż więcej
Źródło:
Cell communication and signaling : CCS [Cell Commun Signal] 2023 Jun 14; Vol. 21 (1), pp. 131. Date of Electronic Publication: 2023 Jun 14.
Typ publikacji:
Video-Audio Media; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Glycogen Synthase Kinase 3*
Lymphoma, Non-Hodgkin*
Humans ; Glycogen Synthase Kinase 3 beta ; beta Catenin
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin's Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study.
Autorzy:
Wang T; Department of Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Nanlishi Road No. 56, Xicheng District, Beijing, 100045, People's Republic of China. .
Zhu X; Department of Hematology, Chinese Academy of Medical Sciences, Hematology Hospital, Heping District, Tianjing, China.
Chen Y; Department of Hematology, Chinese Academy of Medical Sciences, Hematology Hospital, Heping District, Tianjing, China.
Shen S; Department of Hematology, Shanghai Children's Medical Center, Dongfang Road, Shanghai, China.
Tang Y; Department/Center of Hematology-Oncology, Children's Hospital of Zhejiang University School of Medicine, Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health, Gongshu District, Hangzhou City, Zhejiang Province, China.
Zhang J; Department/Center of Hematology-Oncology, Children's Hospital of Zhejiang University School of Medicine, Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health, Gongshu District, Hangzhou City, Zhejiang Province, China.
He Y; Department of Pediatric Hematology/Oncology, Guangzhou Women and Children's Medical Center, 9 Jinsui Road, Guangzhou, China.
Zhang H; Department of Pediatric Hematology/Oncology, Guangzhou Women and Children's Medical Center, 9 Jinsui Road, Guangzhou, China.
Gao J; Department of Hematology, West China Second University Hospital, Chengdu, Sichuan Province, China.
Fang J; Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, West Yanjiang Road, Guangzhou, China.
Liu R; Department of Hematology, Children's Hospital Capital Institute of Pediatrics, Chaoyang District, Beijing, China.
Wu X; Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Sun J; Medical Department, Sanofi, Shanghai, China.
Zhang M; Medical Department, Sanofi, Shanghai, China.
Pokaż więcej
Źródło:
Drugs in R&D [Drugs R D] 2023 Jun; Vol. 23 (2), pp. 129-140. Date of Electronic Publication: 2023 May 10.
Typ publikacji:
Clinical Trial, Phase IV; Journal Article; Multicenter Study
MeSH Terms:
Hyperuricemia*/complications
Hyperuricemia*/drug therapy
Lymphoma, Non-Hodgkin*/complications
Leukemia*/complications
Recombinant Proteins*/adverse effects
Recombinant Proteins*/therapeutic use
Uric Acid ; China ; Humans ; Male ; Female ; Child, Preschool ; Child
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Increased plasma endostatin and GDF15 in indolent non-Hodgkin lymphoma.
Autorzy:
Hidman J; Department of Medical Science, Uppsala University, Uppsala, Sweden.; Centre for Clinical Research Västmanland, Västmanland County Hospital, Uppsala University, Uppsala, Sweden.; Department of Medicine, Västmanland County Hospital, Västerås, Sweden.
Larsson A; Department of Medical Science, Uppsala University, Uppsala, Sweden.; Department of Clinical Chemistry, Uppsala University Hospital, Uppsala, Sweden.
Thulin M; Department of Mathematics, Uppsala University, Uppsala, Sweden.
Karlsson T; Department of Medical Science, Uppsala University, Uppsala, Sweden.; Department of Haematology, Uppsala University Hospital, Uppsala, Sweden.
Pokaż więcej
Źródło:
Upsala journal of medical sciences [Ups J Med Sci] 2023 May 09; Vol. 128. Date of Electronic Publication: 2023 May 09 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Endostatins*
Lymphoma, Non-Hodgkin*
Humans ; Growth Differentiation Factor 15 ; Lipocalin-2 ; Matrix Metalloproteinase 9 ; Disease Progression
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma.
Autorzy:
Mohammadnezhad L; Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), AOUP Paolo Giaccone, 90127 Palermo, Italy.; Department of Sciences for Health Promotion and Mother-Child Care 'G. D'Alessandro', University of Palermo, 90127 Palermo, Italy.
Shekarkar Azgomi M; Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), AOUP Paolo Giaccone, 90127 Palermo, Italy.; Department of Biomedicine, Neuroscience and Advanced Diagnosis (BIND), University of Palermo, 90127 Palermo, Italy.
La Manna MP; Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), AOUP Paolo Giaccone, 90127 Palermo, Italy.; Department of Biomedicine, Neuroscience and Advanced Diagnosis (BIND), University of Palermo, 90127 Palermo, Italy.
Guggino G; Department of Sciences for Health Promotion and Mother-Child Care 'G. D'Alessandro', University of Palermo, 90127 Palermo, Italy.
Botta C; Department of Sciences for Health Promotion and Mother-Child Care 'G. D'Alessandro', University of Palermo, 90127 Palermo, Italy.
Dieli F; Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), AOUP Paolo Giaccone, 90127 Palermo, Italy.; Department of Biomedicine, Neuroscience and Advanced Diagnosis (BIND), University of Palermo, 90127 Palermo, Italy.
Caccamo N; Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), AOUP Paolo Giaccone, 90127 Palermo, Italy.; Department of Biomedicine, Neuroscience and Advanced Diagnosis (BIND), University of Palermo, 90127 Palermo, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 May 07; Vol. 24 (9). Date of Electronic Publication: 2023 May 07.
Typ publikacji:
Journal Article
MeSH Terms:
Sjogren's Syndrome*/genetics
Lymphoma, Large B-Cell, Diffuse*/genetics
Lymphoma, Large B-Cell, Diffuse*/pathology
Lymphoma, Non-Hodgkin*
Humans ; Signal Transduction ; Receptors, Antigen, B-Cell/genetics ; Guanine Nucleotide Exchange Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Non-hodgkin's lymphoma masquerading as a right atrial mass.
Autorzy:
Arora P; Department of Anaesthesiology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Mujahid OM; Department of Anaesthesiology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Singha SK; Department of Anaesthesiology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Pokaż więcej
Źródło:
Annals of cardiac anaesthesia [Ann Card Anaesth] 2023 Apr-Jun; Vol. 26 (2), pp. 209-210.
Typ publikacji:
Journal Article
MeSH Terms:
Atrial Fibrillation*
Lymphoma, Non-Hodgkin*/diagnostic imaging
Lymphoma, Non-Hodgkin*/pathology
Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Optic nerve infiltration in systemic non Hodgkin lymphoma.
Autorzy:
Cameron CA; Discipline of Ophthalmology and Visual Sciences, The University of Adelaide and the South Australian Institute of Ophthalmology, Adelaide, Australia.
Juniat V; Discipline of Ophthalmology and Visual Sciences, The University of Adelaide and the South Australian Institute of Ophthalmology, Adelaide, Australia.
Tong JY; Sydney Eye Hospital, Sydney, Australia.
Crompton JL; Discipline of Ophthalmology and Visual Sciences, The University of Adelaide and the South Australian Institute of Ophthalmology, Adelaide, Australia.
Davis G; Discipline of Ophthalmology and Visual Sciences, The University of Adelaide and the South Australian Institute of Ophthalmology, Adelaide, Australia.
Patel S; Department of Medical Imaging, Royal Adelaide Hospital, Adelaide, Australia.
Selva D; Discipline of Ophthalmology and Visual Sciences, The University of Adelaide and the South Australian Institute of Ophthalmology, Adelaide, Australia.
Pokaż więcej
Źródło:
Orbit (Amsterdam, Netherlands) [Orbit] 2023 Apr; Vol. 42 (2), pp. 216-220. Date of Electronic Publication: 2021 Nov 02.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/complications
Lymphoma, Non-Hodgkin*/diagnosis
Lymphoma, Non-Hodgkin*/pathology
Optic Nerve Diseases*/diagnosis
Lymphoma*/pathology
Papilledema*
Male ; Humans ; Middle Aged ; Optic Nerve/diagnostic imaging ; Magnetic Resonance Imaging
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Advanced penile lymphoma: Case report and review of the literature.
Autorzy:
Arambulo S; Department of Medical Oncology, Hospital María Auxiliadora, Lima, Peru.
Calle A; Department of Medical Oncology, Hospital María Auxiliadora; Aliada Oncological Center, Lima, Peru.
Vela JM; Department of Medical Oncology, Hospital María Auxiliadora, Lima, Peru.
Sotelo MJ; Department of Medical Oncology, Hospital María Auxiliadora; Aliada Oncological Center; Oncological Research Unit, Clínica San Gabriel, Lima, Peru.
Pokaż więcej
Źródło:
Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Apr-Jun; Vol. 19 (3), pp. 823-825.
Typ publikacji:
Review; Case Reports
MeSH Terms:
Lymphoma*/drug therapy
Lymphoma, Non-Hodgkin*/diagnosis
Lymphoma, Non-Hodgkin*/drug therapy
Male ; Humans ; Rituximab/therapeutic use ; Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Penis/surgery ; Penis/pathology
Recenzja
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics.
Autorzy:
Hoffmann C; Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany. .
Mohr C; Department of Oral and Maxillofacial Surgery, University of Duisburg-Essen, Kliniken-Essen-Mitte, Essen, Germany.
Johansson P; Institute of Cell Biology (Cancer Research), Faculty of Medicine, University of Duisburg-Essen, Essen, Germany.
Eckstein A; Department of Ophthalmology, University Hospital of Essen, Essen, Germany.
Huettmann A; Department of Hematology, University Hospital Essen, Essen, Germany.
von Tresckow J; Department of Hematology, University Hospital Essen, Essen, Germany.
Göricke S; Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Deuschl C; Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Poettgen C; Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Gauler T; Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Guberina N; Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Moliavi S; Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Bechrakis N; Department of Ophthalmology, University Hospital of Essen, Essen, Germany.
Stuschke M; Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Guberina M; Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Mar 23; Vol. 13 (1), pp. 4792. Date of Electronic Publication: 2023 Mar 23.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/diagnostic imaging
Lymphoma, Non-Hodgkin*/radiotherapy
Lymphoma, Non-Hodgkin*/drug therapy
Lymphoma*/diagnostic imaging
Lymphoma*/radiotherapy
Lymphoma*/drug therapy
Humans ; Follow-Up Studies ; Retrospective Studies ; Magnetic Resonance Imaging ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas.
Autorzy:
Sortais C; Department of Hematology, CHU de Nantes, Nantes, France.
Cordeil S; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Bourbon E; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Idlhaj M; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Ferrant E; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Safar V; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Golfier C; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Lazareth A; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Bouafia-Sauvy F; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Tordo J; Department of Nuclear Medicine, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Ghesquières H; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.; Lymphoma Immuno-biology (LIB) Research Unit, Claude Bernard Lyon 1 University, Lyon, France.
Sesques P; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Bachy E; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.; Lymphoma Immuno-biology (LIB) Research Unit, Claude Bernard Lyon 1 University, Lyon, France.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 707-711. Date of Electronic Publication: 2022 Dec 27.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/diagnosis
Lymphoma, Non-Hodgkin*/therapy
Humans ; Immunotherapy, Adoptive/adverse effects ; T-Lymphocytes ; Antigens, CD19
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
Autorzy:
Qualls D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Noy A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Straus D; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Matasar M; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Moskowitz C; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Seshan V; Department of Epidemiology and Biostatistics, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dogan A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Salles G; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Younes A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Batlevi CL; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 738-741. Date of Electronic Publication: 2023 Jan 15.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, Non-Hodgkin*/diagnosis
Lymphoma, Non-Hodgkin*/drug therapy
Lymphoma, Non-Hodgkin*/genetics
Neoplasm Recurrence, Local*/drug therapy
Neoplasm Recurrence, Local*/genetics
Humans ; CREB-Binding Protein/genetics ; E1A-Associated p300 Protein/genetics ; Epigenesis, Genetic ; Mutation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Ex vivo NMR metabolomics approach using cerebrospinal fluid for the diagnosis of primary CNS lymphoma: Correlation with MR imaging characteristics.
Autorzy:
Kim JH; Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
An YJ; College of Pharmacy, Natural Product Research Institute, Seoul National University, Seoul, Republic of Korea.
Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Kim JE; Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea.
Park S; College of Pharmacy, Natural Product Research Institute, Seoul National University, Seoul, Republic of Korea.
Choi SH; Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Center for Nanoparticle Research, Institute for Basic Science, and School of Chemical and Biological Engineering, Seoul National University, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Feb; Vol. 12 (4), pp. 4679-4689. Date of Electronic Publication: 2022 Aug 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Central Nervous System Neoplasms*/diagnostic imaging
Central Nervous System Neoplasms*/cerebrospinal fluid
Lymphoma*/diagnostic imaging
Lymphoma*/pathology
Lymphoma, Non-Hodgkin*/diagnostic imaging
Lymphoma, Non-Hodgkin*/pathology
Humans ; Magnetic Resonance Imaging/methods ; Magnetic Resonance Spectroscopy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Outcomes of coronavirus disease 2019 (COVID-19) and risk factors associated with severe COVID-19 in patients with mature B-cell non-Hodgkin lymphomas: A US electronic health record cohort study.
Autorzy:
Yue X; AbbVie, Inc., North Chicago, Illinois, USA.
Hallett D; AbbVie, Inc., North Chicago, Illinois, USA.
Liu Y; AbbVie, Inc., North Chicago, Illinois, USA.
Basa E; AbbVie, Inc., North Chicago, Illinois, USA.
McNeill A; AbbVie, Inc., North Chicago, Illinois, USA.
Dean JP; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California, USA.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2023 Feb; Vol. 110 (2), pp. 177-187. Date of Electronic Publication: 2022 Nov 15.
Typ publikacji:
Journal Article
MeSH Terms:
COVID-19*/complications
COVID-19*/epidemiology
Diabetes Mellitus, Type 2*
Lymphoma, Non-Hodgkin*/diagnosis
Lymphoma, Non-Hodgkin*/epidemiology
Neoplasms*
Humans ; Male ; Aged ; Aged, 80 and over ; Cohort Studies ; Electronic Health Records ; Risk Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models.
Autorzy:
Ke H; Hanx Pharmaceuticals, Inc., Hangzhou, China.
Zhang F; Hanx Pharmaceuticals, Inc., Hangzhou, China.
Wang J; Crown Bioscience, Inc., San Diego, USA.
Xiong L; Crown Bioscience, Inc., San Diego, USA.
An X; Crown Bioscience, Inc., San Diego, USA.
Tu X; Crown Bioscience, Inc., San Diego, USA.
Chen C; Hanx Pharmaceuticals, Inc., Hangzhou, China.
Wang Y; Crown Bioscience, Inc., San Diego, USA.
Mao B; Crown Bioscience, Inc., San Diego, USA.
Guo S; Crown Bioscience, Inc., San Diego, USA.
Ju C; GemPhamatech, Co., Ltd., Nanjing, China.
He X; Shanghai Model Organisms Center, Inc. (SMOC), Shanghai, China.
Sun R; Shanghai Model Organisms Center, Inc. (SMOC), Shanghai, China.
Zhang L; Hanx Pharmaceuticals, Inc., Hangzhou, China.
O'Connor OA; Division of Hematology and Oncology, University of Virginia Cancer Center, University of Virginia, Charlottesville, USA.
Li QX; Hanx Pharmaceuticals, Inc., Hangzhou, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Apr 03; Vol. 13 (1), pp. 5419. Date of Electronic Publication: 2023 Apr 03.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*
Antibodies, Bispecific*/pharmacology
Antibodies, Bispecific*/therapeutic use
Neoplasms*/metabolism
Mice ; Animals ; Humans ; B7-H1 Antigen ; Leukocytes, Mononuclear/metabolism ; Antibodies, Monoclonal/therapeutic use ; Immunologic Factors/therapeutic use ; CD47 Antigen ; Tumor Microenvironment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Enhancing information on stage at diagnosis of cancer in Africa.
Autorzy:
Parkin DM; Nuffield Department of Population Health, University of Oxford, Oxford, UK.; Cancer Surveillance Unit, International Agency for Research on Cancer, Lyon, France.
Liu B; African Cancer Registry Network, Oxford, UK.
Adoubi I; Ministere de la Sant, Programme National de Lutte Contre le Cancer, Abidjan, Cote d'Ivoire.
Makouanzi AS; Service de Cancerologie, Hôpital General Adolphe Sicé, Pointe Noir, Congo Brazzaville.
Masalu N; Bugando Hospital, Mwanza, Tanzania.
Mrema C; Oncology Department, Benjamin Mpaka Zonal Referral Hospital, Dodoma, Tanzania.
Ndlovu N; Department of Oncology, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.; Radiotherapy Centre, Parirenyatwa Group of Hospitals, Harare, Zimbabwe.
Omonisi A; Ekiti Cancer Registry, Ekiti State University Teaching Hospital, Ado-Ekiti, Nigeria.
Traore B; Service de Cancérologie, Hôpital National Donka, Faculté des Sciences Techniques de la Santé, Université Gamal Abdel Nasser de Conakry, Conakry, Guinee.
Joko-Fru Y; Nuffield Department of Population Health, University of Oxford, Oxford, UK.; African Cancer Registry Network, Oxford, UK.
Pokaż więcej
Źródło:
Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2023 Apr; Vol. 62 (4), pp. 335-341. Date of Electronic Publication: 2023 Apr 27.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms*/diagnosis
Neoplasms*/epidemiology
Neoplasms*/pathology
Lymphoma, Non-Hodgkin*
Female ; Humans ; Neoplasm Staging ; Registries ; Prognosis ; Africa/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prognostic value of cross-lineage expression of the myeloid-associated antigens CD13 and CD33 in adult B-lymphoblastic leukemia: A large real-world study of 1005 patients.
Autorzy:
Liao H; Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Lai H; Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Chen J; Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Shuai X; Department of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Zhang X; Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Yang Y; Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Lyu M; Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Zheng Q; Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (8), pp. 9615-9626. Date of Electronic Publication: 2023 Mar 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Lymphoma, Non-Hodgkin*
Humans ; Adult ; Prognosis ; Antigens, CD/metabolism ; Retrospective Studies ; CD13 Antigens/metabolism ; Acute Disease ; Sialic Acid Binding Ig-like Lectin 3
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
No association of malignant B-cell non-Hodgkin lymphomas with ipsilateral SARS-CoV-2 vaccination.
Autorzy:
Claaß LV; Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Mayr P; Department of Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.
Paschold L; Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Weber T; Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Terziev D; Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Jehs B; Department of Diagnostic and Interventional Radiology, Medical Faculty, University of Augsburg, Augsburg, Germany.
Brill R; Clinic and Policlinic of Radiology, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.
Dober J; Clinic and Policlinic of Radiology, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.
Märkl B; General Pathology and Molecular Diagnostics, Medical Faculty, University of Augsburg, Augsburg, Germany.
Wickenhauser C; Institute of Pathology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Czapiewski P; Department of Pathology, Medical Faculty, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.; Department of Pathology Dessau Medical Centre, Institute of Pathology, Dessau, Germany.
Trepel M; Department of Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.
Claus R; General Pathology and Molecular Diagnostics, Medical Faculty, University of Augsburg, Augsburg, Germany.; Comprehensive Cancer Center Augsburg (CCCA), Medical Faculty, University of Augsburg, Augsburg, Germany.
Binder M; Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (8), pp. 9313-9321. Date of Electronic Publication: 2023 Feb 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
COVID-19*/prevention & control
Lymphoma*/pathology
Lymphoma, Non-Hodgkin*/pathology
Humans ; COVID-19 Vaccines/adverse effects ; SARS-CoV-2 ; Vaccination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma.
Autorzy:
Kong X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhang X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Ding M; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Feng X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Dong M; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhang L; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Fu X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Li L; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Li X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Sun Z; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yan J; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Wang X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Wu X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Chen Q; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhang M; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhu L; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (7), pp. 8134-8143. Date of Electronic Publication: 2023 Jan 25.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Lymphoma, Non-Hodgkin*/drug therapy
Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Decitabine/adverse effects ; Rituximab/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 41-60 z 3129

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies